Skip to content
Tech News
← Back to articles

‘Megacluster’ of genes enables bacteria to make potent antibiotic mixture

read original more articles
Why This Matters

The discovery of a 'megacluster' of genes in bacteria that enables the production of potent antibiotic mixtures offers a promising new avenue to combat antibiotic resistance. This breakthrough could lead to the development of more effective antibiotics, addressing a critical global health challenge. By harnessing natural bacterial mechanisms, the tech and pharmaceutical industries can accelerate the creation of innovative treatments to stay ahead of resistant pathogens.

Key Takeaways

Natural products have been the cornerstone of antibiotic development since Alexander Fleming found that a compound, penicillin, made by a mould could kill bacteria. Today, natural products and molecules inspired by these compounds comprise more than 80% of clinically approved antibiotics. The spread of antibiotic resistance among pathogenic bacteria, however, has rendered entire classes of these life-saving drugs ineffective1, posing a global threat to human health and modern medicine that must be met with a robust effort to discover, develop and deploy new treatments. Fortunately, computational, microbiological and medicinal-chemistry studies over the past decade (see refs 2–7, for example) suggest that approaches inspired by nature have the potential to overcome multidrug resistance. Writing in Nature, Gordzevich et al.8 report a fresh strategy for using natural products to combat antibiotic resistance, inspired by a discovery in bacteria.

doi: https://doi.org/10.1038/d41586-026-01804-1

References Antimicrobial Resistance Collaborators. Lancet 399, 629–655 (2022). Ling, L. L. et al. Nature 517, 455–459 (2015). Imai, Y. et al. Nature 576, 459–464 (2019). Wang, Z. et al. Nature 601, 606–611 (2022). Hover, B. M. et al. Nature Microbiol. 3, 415–422 (2018). Smith, P. A. et al. Nature 561, 189–194 (2018). Wan, F., Torres, M. D. T., Peng, J. & de la Fuente-Nunez, C. Nature Biomed. Eng. 8, 854–871 (2024). Gordzevich, R. et al. Nature https://doi.org/10.1038/s41586-026-10647-9 (2026). Atanasov, A. G. et al. Nature Rev. Drug Discov. 20, 200–216 (2021). Zlitni, S., Ferruccio, L. F. & Brown, E. D. Nature Chem. Biol. 9, 796–804 (2013). Carfrae, L. A. et al. Nature Microbiol. 5, 93–101 (2020). Meyer, K. J. & Nodwell, J. R. Nature Microbiol. 6, 1118–1128 (2021). Blaskovich, M. A. T. & Cooper, M. A. npj Antimicrob. Resist. 3, 47 (2025). Download references

Competing Interests S.T.R. is an employee of Genentech, Inc., a member of the Roche Group.

Related Articles

Subjects